Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1) + Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2) + Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3) + Infanrix Hexa + Menjugate + Prevenar
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Serogroup B Meningococcal Meningitis
Conditions
Serogroup B Meningococcal Meningitis
Trial Timeline
Mar 1, 2008 → Jan 1, 2010
NCT ID
NCT00657709About Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1) + Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2) + Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3) + Infanrix Hexa + Menjugate + Prevenar
Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1) + Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2) + Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3) + Infanrix Hexa + Menjugate + Prevenar is a phase 3 stage product being developed by Novartis for Serogroup B Meningococcal Meningitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00657709. Target conditions include Serogroup B Meningococcal Meningitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00657709 | Phase 3 | Completed |
Competing Products
3 competing products in Serogroup B Meningococcal Meningitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| meningococcal B vaccine & meningococcal ACYW conjugate vaccine | Novartis | Phase 2 | 52 |
| Meningococcal (group B) multicomponent recombinant adsorbed vaccine | Novartis | Phase 3 | 77 |
| rLP2086 | Pfizer | Phase 2 | 51 |